Levi & Korsinsky LLP
04/17/2026 | Press release | Distributed by Public on 04/17/2026 10:01
Missed the Beat: Boston Scientific Accused of Concealing EP Segment Headwinds
Boston Scientific told investors its heart rhythm business was growing fast. Growth looked strong and sustainable. The company said its electrophysiology division would keep expanding, fueled by adoption of its FARAPULSE technology.
But investors say the reality was very different.
In July 2025, executives reported strong results and raised guidance, promising sustained growth in the U.S. EP business. Through September and October 2025, leadership continued telling investors the market was expanding and the company could keep gaining share. The lawsuit says management already knew growth was hitting a wall. Adverse trends affecting procedure volumes were emerging, competition was rising, and regulatory and reimbursement pressures were building.
Then, on February 4, 2026, the truth came out. Boston Scientific reported weaker-than-expected EP results and issued softer guidance for 2026.
Investors reacted instantly. The stock dropped about 18% in a single day.
Now, more investors are joining the lawsuit.
Levi & Korsinsky LLP published this content on April 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 17, 2026 at 16:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]